Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


31.07.2017

1 Am J Ind Med
10 Anticancer Res
2 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
4 Cancer Res
1 Clin Exp Metastasis
3 Clin Lung Cancer
1 Eur Respir J
2 Genes Chromosomes Cancer
2 Int J Cancer
7 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
9 J Thorac Oncol
2 Lancet Respir Med
2 Lung Cancer (Auckl)
1 Mol Cancer Ther
2 Oncogene
1 Oncol Rep
7 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Ind Med

  1. KOHYAMA N, Fujiki M, Kishimoto T, Morinaga K, et al
    Lung cancer in a patient with predominantly short tremolite fibers in his lung.
    Am J Ind Med. 2017 Jul 26. doi: 10.1002/ajim.22748.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. TAMIYA A, Tamiya M, Nishihara T, Shiroyama T, et al
    Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
    Anticancer Res. 2017;37:4177-4182.
    PubMed     Text format     Abstract available

  3. FLAMINI V, Jiang WG, Cui Y
    Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4319-4327.
    PubMed     Text format     Abstract available

  4. ZHAO Z, Cheng S, Zabkiewicz C, Chen J, et al
    Reduced Expression of RanBPM Is Associated with Poorer Survival from Lung Cancer and Increased Proliferation and Invasion of Lung Cancer Cells In Vitro.
    Anticancer Res. 2017;37:4389-4397.
    PubMed     Text format     Abstract available

  5. YANG F, Gu Y, Zhao Z, Huang J, et al
    NHERF1 Suppresses Lung Cancer Cell Migration by Regulation of Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:4405-4414.
    PubMed     Text format     Abstract available

  6. WANG F, Lu J, Li S, Huo X, et al
    Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Anticancer Res. 2017;37:4515-4522.
    PubMed     Text format     Abstract available

  7. YANG Y, Sun N, Sun P, Zhang L, et al
    Clinical Characteristics and Prognosis of Elderly Small Cell Lung Cancer Patients Complicated with Hyponatremia: A Retrospective Analysis.
    Anticancer Res. 2017;37:4681-4686.
    PubMed     Text format     Abstract available

  8. WONG W, Sun P, Mu Z, Liu J, et al
    Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4687-4691.
    PubMed     Text format     Abstract available

  9. HE Q, Bi X, Ren C, Wang Y, et al
    Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.
    Anticancer Res. 2017;37:4711-4716.
    PubMed     Text format     Abstract available

  10. TAKAMORI S, Toyokawa G, Okamoto I, Takada K, et al
    Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2017;37:4223-4228.
    PubMed     Text format     Abstract available

  11. YU Z, Sanders AJ, Owen S, Cheng S, et al
    Expression of Osteoprotegrin Is Enhanced in Lung Cancer Tissues and Promotes Aggressive Cellular Traits in H3122 Lung Cancer Cells.
    Anticancer Res. 2017;37:4277-4283.
    PubMed     Text format     Abstract available


    Cancer

  12. PISAPIA P, Lozano MD, Vigliar E, Bellevicine C, et al
    ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Cancer. 2017 Jul 25. doi: 10.1002/cncy.21899.
    PubMed     Text format     Abstract available

  13. PILLAI RN, Behera M, Berry LD, Rossi MR, et al
    HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30869.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  14. KIM HK, Heo MH, Lee HS, Sun JM, et al
    Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Cancer Chemother Pharmacol. 2017 Jul 21. doi: 10.1007/s00280-017-3396.
    PubMed     Text format     Abstract available


    Cancer Lett

  15. STAPELFELD C, Neumann KT, Maser E
    Different inhibitory potential of sex hormones on NNK detoxification in vitro: a possible explanation for gender-specific lung cancer risk.
    Cancer Lett. 2017 Jul 22. pii: S0304-3835(17)30451.
    PubMed     Text format     Abstract available


    Cancer Res

  16. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
    The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
    Cancer Res. 2017;77:14-26.
    PubMed     Text format     Abstract available

  17. HAN SY, Ko A, Kitano H, Choi CH, et al
    Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
    Cancer Res. 2017;77:343-354.
    PubMed     Text format     Abstract available

  18. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
    A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
    Cancer Res. 2017;77:153-163.
    PubMed     Text format     Abstract available

  19. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
    PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
    Cancer Res. 2017;77:187-197.
    PubMed     Text format     Abstract available


    Clin Exp Metastasis

  20. JENSEN GL, Tang C, Hess KR, Liao Z, et al
    Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer.
    Clin Exp Metastasis. 2017 Jul 25. doi: 10.1007/s10585-017-9850.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  21. VERMA V, Simone CB 2nd
    Surgery Versus Conventional Radiation Therapy for T1-2 N0 M0 Small-cell Lung Cancer: A Fair Comparison?
    Clin Lung Cancer. 2017 Jul 6. pii: S1525-7304(17)30201.
    PubMed     Text format    

  22. TAKAMORI S, Toyokawa G, Takada K, Shoji F, et al
    Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
    Clin Lung Cancer. 2017 Jul 6. pii: S1525-7304(17)30202.
    PubMed     Text format     Abstract available

  23. YANG JC, Mok T, Han B, Orlando M, et al
    A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2017 Jul 6. pii: S1525-7304(17)30200.
    PubMed     Text format     Abstract available


    Eur Respir J

  24. PLUVY J, Brosseau S, Naltet C, Opsomer MA, et al
    Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    Genes Chromosomes Cancer

  25. LEICHSENRING J, Volckmar AL, Magios N, Morais de Oliveira CM, et al
    Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
    Genes Chromosomes Cancer. 2017;56:214-220.
    PubMed     Text format     Abstract available

  26. GOW CH, Chang HT, Lim CK, Liu CY, et al
    Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
    Genes Chromosomes Cancer. 2017;56:373-381.
    PubMed     Text format     Abstract available


    Int J Cancer

  27. LI W, Xie SH, Tse LA, Lagergren J, et al
    Digitalis Use and Lung Cancer Risk by Histological Type in Men.
    Int J Cancer. 2017 Jul 27. doi: 10.1002/ijc.30908.
    PubMed     Text format     Abstract available

  28. MORAVCIKOVA E, Krepela E, Donnenberg VS, Donnenberg AD, et al
    BOK displays cell death-independent tumor suppressor activity in non-small cell lung carcinoma.
    Int J Cancer. 2017 Jul 26. doi: 10.1002/ijc.30906.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  29. RIEBER J, Abbassi-Senger N, Adebahr S, Andratschke N, et al
    Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
    Int J Radiat Oncol Biol Phys. 2017;98:511-520.
    PubMed     Text format     Abstract available

  30. WAHL DR, Nguyen PL, Santiago M, Yousefi K, et al
    Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.
    Int J Radiat Oncol Biol Phys. 2017;98:726-732.
    PubMed     Text format     Abstract available

  31. MIDDELBURG JG, Mast ME, de Kroon M, Jobsen JJ, et al
    Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2017;98:843-849.
    PubMed     Text format     Abstract available

  32. FANG P, He W, Gomez DR, Hoffman KE, et al
    Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
    Int J Radiat Oncol Biol Phys. 2017;98:748-757.
    PubMed     Text format     Abstract available

  33. BANG A, Wilhite TJ, Pike LRG, Cagney DN, et al
    Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;98:344-351.
    PubMed     Text format     Abstract available

  34. BASCH E, Pugh SL, Dueck AC, Mitchell SA, et al
    Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2017;98:409-418.
    PubMed     Text format     Abstract available

  35. WANG CJ, Christie A, Lin MH, Jung M, et al
    Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Int J Radiat Oncol Biol Phys. 2017;98:91-100.
    PubMed     Text format     Abstract available


    J Clin Oncol

  36. YANG JJ, Yu D, Takata Y, Smith-Warner SA, et al
    Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis.
    J Clin Oncol. 2017 Jul 25:JCO2017733329. doi: 10.1200/JCO.2017.73.3329.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  37. SONG MA, Benowitz NL, Berman M, Brasky TM, et al
    Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  38. SCHAHEEN LW, D'Cunha J
    The slippery slope of nonoperative therapy in early-stage lung cancer.
    J Thorac Cardiovasc Surg. 2017 Jun 10. pii: S0022-5223(17)31178.
    PubMed     Text format    


    J Thorac Oncol

  39. CHO BC, Kim DW, Bearz A, Laurie SA, et al
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
    PubMed     Text format     Abstract available

  40. LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
    The current role of whole brain radiation therapy in non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
    PubMed     Text format     Abstract available

  41. NORSKOV MS, Dahl M, Tybjaerg-Hansen A
    Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
    J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
    PubMed     Text format     Abstract available

  42. STONE E, Slatore CG
    The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
    J Thorac Oncol. 2017;12:1174-1176.
    PubMed     Text format    

  43. SHOJAEE S, Vachani A, Nana-Sinkam P
    The Financial Implications of Lung Cancer Screening: Is It Worth It?
    J Thorac Oncol. 2017;12:1177-1179.
    PubMed     Text format    

  44. YANAGISAWA S, Miyauchi E, Ichinose M
    Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
    J Thorac Oncol. 2017;12:e114-e116.
    PubMed     Text format    

  45. KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
    A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e128-e130.
    PubMed     Text format    

  46. SAFIRI S, Ayubi E
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e130-e131.
    PubMed     Text format    

  47. LI C, Huang C, Mok TS, Zhuang W, et al
    Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  48. YANG JJ, Zhou C, Huang Y, Feng J, et al
    Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Lancet Respir Med. 2017 Jul 19. pii: S2213-2600(17)30262.
    PubMed     Text format     Abstract available

  49. ROSELL R, Karachaliou N
    Brain metastases in patients with EGFR-mutant non-small-cell lung cancer.
    Lancet Respir Med. 2017 Jul 19. pii: S2213-2600(17)30265.
    PubMed     Text format    


    Lung Cancer (Auckl)

  50. ROSSI G, Jocolle G, Conti A, Tiseo M, et al
    Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives.
    Lung Cancer (Auckl). 2017;8:45-55.
    PubMed     Text format     Abstract available

  51. COBO M, Gutierrez V, Villatoro R, Trigo JM, et al
    Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.
    Lung Cancer (Auckl). 2017;8:57-66.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  52. SHIEN K, Papadimitrakopoulou VA, Ruder D, Behrens C, et al
    JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
    Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016.
    PubMed     Text format     Abstract available


    Oncogene

  53. GARNETT S, Dutchak KL, McDonough RV, Dankort D, et al
    p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available

  54. UMEDA Y, Hasegawa Y, Otsuka M, Ariki S, et al
    Surfactant protein D inhibits activation of non-small cell lung cancer-associated mutant EGFR and affects clinical outcomes of patients.
    Oncogene. 2017 Jul 24. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  55. ZHOU F, Nie L, Feng D, Guo S, et al
    MicroRNA-379 acts as a tumor suppressor in non-small cell lung cancer by targeting the IGF1R-mediated AKT and ERK pathways.
    Oncol Rep. 2017 Jul 18. doi: 10.3892/or.2017.5835.
    PubMed     Text format     Abstract available


    PLoS One

  56. KOLEK V, Grygarkova I, Koubkova L, Skrickova J, et al
    Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up.
    PLoS One. 2017;12:e0181803.
    PubMed     Text format     Abstract available

  57. OH TK, Jeon JH, Lee JM, Kim MS, et al
    Investigation of opioid use and long-term oncologic outcomes for non-small cell lung cancer patients treated with surgery.
    PLoS One. 2017;12:e0181672.
    PubMed     Text format     Abstract available

  58. AL-SAAD S, Richardsen E, Kilvaer TK, Donnem T, et al
    The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    PLoS One. 2017;12:e0181527.
    PubMed     Text format     Abstract available

  59. PATNAIK SK, Kannisto ED, Mallick R, Vachani A, et al
    Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.
    PLoS One. 2017;12:e0181926.
    PubMed     Text format     Abstract available

  60. SARIN N, Engel F, Kalayda GV, Mannewitz M, et al
    Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    PLoS One. 2017;12:e0181081.
    PubMed     Text format     Abstract available

  61. BANJARA M, Ghosh C, Dadas A, Mazzone P, et al
    Detection of brain-directed autoantibodies in the serum of non-small cell lung cancer patients.
    PLoS One. 2017;12:e0181409.
    PubMed     Text format     Abstract available

  62. TANG ZM, Ling ZG, Wang CM, Wu YB, et al
    Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
    PLoS One. 2017;12:e0182117.
    PubMed     Text format     Abstract available


    Thorax

  63. LOCOCO F, Cardillo G, Veronesi G
    Does a lung cancer screening programme promote smoking cessation?
    Thorax. 2017 Jul 26. pii: thoraxjnl-2017-210621.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: